新闻

RapAdmin

NeuralAging
NeuralAging2752×1536 421 KB

Aging is the leading risk factor for cognitive impairment and neurodegeneration, characterized by systemic immune activation, synaptic remodeling, and glial cell reactivity. To dissect the molecular drivers of these changes, researchers leveraged the naturally short-lived African turquoise killifish (Nothobranchius furzeri ) to construct a multi-omic atlas of brain aging. Analyzing both the short-lived GRZ strain and the longer-lived ZMZ-1001 strain across both sexes, the team integrated single-nuclei RNA-sequencing (snRNA-seq), single-nuclei ATAC-seq, and bulk ATAC-seq to map transcriptional and epigenetic shifts over the organism’s lifespan.

The data revealed a pronounced, sex- and strain-independent expansion of microglia—the brain’s resident immune cells—in older brains. These microglia shifted away from homeostatic functions toward highly activated, inflammatory states mirroring Damage-Associated Microglia (DAM) and Interferon-Response Microglia (IRM) seen in aging mammals. By analyzing transcription factor activity and chromatin footprints, the researchers identified hyperactive glucocorticoid receptor (nr3c1) signaling as a primary driver of this transcriptomic remodeling, fueled by age-related increases in systemic cortisol production.

To test if this pathway was druggable, the team intervened with mifepristone, an FDA-approved competitive antagonist of the glucocorticoid receptor. Initiating treatment at middle age (10 weeks) and evaluating the brain at old age (16 weeks), they found that mifepristone significantly blunted the molecular hallmarks of brain aging. The intervention successfully reversed age-related microglial expansion, dampened inflammatory gene expression, and rescued vital cellular pathways involving proteostasis, cell membrane biology, and RNA metabolism. This strongly suggests that chronic glucocorticoid signaling is not merely a correlate of chronological age, but an actionable driver of neural decline.

Source:

RapAdmin

EpigeneticsSkinAging
EpigeneticsSkinAging2752×1536 468 KB

Our skin serves as the frontline shield against environmental insults, making it a highly accurate reflection of our biological age. However, the precise mechanisms translating lifestyle factors into epigenetic alterations have remained largely opaque. Now, a collaborative study between Beiersdorf AG and University Medicine Greifswald, published in Clinical Epigenetics, brings new clarity to this process by uncovering 37 specific lifestyle, physiological, and pharmacological factors that significantly alter the epigenetic trajectory of human skin.

Rather than looking at standard biological markers, the research team utilized the skin-specific “Bormann clock” to determine the DNA methylation (DNAm) age of epidermal samples from 851 participants. They cross-referenced these epigenetic ages against 326 distinct life factors. The results were telling: 20 factors were robustly linked to decelerated skin aging, while 17 were associated with accelerated aging.

What sets this study apart is its deep dive into how these factors operate. The researchers discovered that age-accelerating factors—such as a history of severe sunburns, solarium / tanning bed use, and elevated 25-hydroxyvitamin D levels—promote “epigenetic drift”. This drift is characterized by a loss of the bimodal DNA methylation patterns necessary for maintaining cellular specificity, particularly in polycomb-repressed regions. Conversely, age-decelerating factors—including high skin moisture, regular swimming, higher education, and the routine use of low-dose aspirin—target transcription elongation regions. Rather than actively rejuvenating the skin, these positive factors seem to stabilize the epigenome, preserving transcriptional integrity and preventing the biological erosion associated with age.

The researchers also matched their findings against known longevity compounds. They demonstrated that patterns induced by topical dihydromyricetin (DHM) and other metabolic modulators share substantial overlap with the CpG sites protected by age-decelerating lifestyle choices. This strongly suggests that the same anti-aging pathways modulated by daily habits can be directly targeted through specific biotech interventions. While the data represents a major step forward, the reliance on correlative population data means we are observing associations rather than definitive causes. Nonetheless, this sweeping epigenetic map provides a vital foundation for next-generation skin longevity interventions.

Context & Impact:

RapAdmin

Autophagy1
Autophagy12752×1536 431 KB

The ultimate holy grail in longevity research isn’t a silver bullet; it is the optimization of a cellular trash disposal system known as autophagy. A 2026 review explicitly links the lifespan-extending benefits of popular pharmacological agents (like rapamycin, metformin, and urolithin A) and lifestyle interventions (dietary restriction, exercise, sleep, and temperature stress) directly to this conserved cellular recycling mechanism. What makes this paradigm-shifting is the mounting evidence that these seemingly disparate biohacking strategies are just different physiological roads leading to the exact same metabolic destination: clearing out misfolded proteins and dysfunctional organelles to prevent age-related decline.

While the causative role of autophagy in lifespan extension is irrefutable in model organisms like yeast, nematodes, and mice—where knocking out autophagy genes completely erases the benefits of fasting or rapamycin—human data remains stubbornly correlational. The core roadblock is the field’s current inability to accurately measure dynamic “autophagic flux” in living human tissues, forcing researchers to rely on noisy, indirect proxies like peripheral blood mononuclear cell (PBMC) profiling.

Despite this analytical gap, the paper highlights actionable insights for human healthspan. From early time-restricted feeding that syncs autophagy to circadian rhythms, to the mechanical stress of resistance training triggering Chaperone-Assisted Selective Autophagy (CASA) in muscle tissue, we are learning precisely how to activate this pathway in an organ-specific manner. Even temperature stress is gaining mechanical clarity, with cold exposure driving systemic lipophagy via hypothalamic signaling. Ultimately, stacking these interventions could provide synergistic healthspan benefits, even as we wait for the clinical flux assays needed to quantify them perfectly in living humans.

Source:

  • Open Access Paper: Links Between Autophagy and Healthy Aging (Review Article)
  • Institution: This research originates from The Buck Institute for Research on Aging in the USA,
  • Journal: published in the Journal of Molecular Biology.
    *Impact Evaluation: The impact score of this journal is 4.7, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.

相关阅读：

RapAdmin

Screenshot 2026-04-03 at 1.51.36 PM
Screenshot 2026-04-03 at 1.51.36 PM1290×744 119 KB

For people interested in longevity who live near Chicago, this looks to be another great conference by the Longevity Global team.

Great speakers, including Hazel Szeto of SS-31 fame. She was one of my favorite speakers at the December Conference at the Buck Institute.

Register today. And, Use discount code RAPAMYCIN50 to get 50% off.

Register here: Longevity CHI 2026 Conference · Luma

Agenda

9:00 am - Longevity vs. Biotech Investing
Moshe Bellows (Maccabee Ventures), Joshua Rogers (Arete Wealth Management), Joshua Barney (Barrington Angels)

​10:00 am - Longevity Startup Showcase
John Ramunas, PhD (Rejuvenation Technologies), Glen Markov, PhD (Rejuvenation Technologies), Ashley Zehnder, PhD (Fauna Bio)

​11:00 am - Frontiers in Aging Biology
Alice Gilman (R3 Biotech), Dr. Sofie Wei, PhD (X-Therma, Inc), Ashley Zehnder, PhD (Fauna Bio), Louise Hecker (PsiloHeal)

​12:00 pm - Catered Networking Lunch

​Afternoon Session

​1:30 pm - Clinical Longevity Medicine
Dr. Hazel Szeto, MD PhD (Stealth BioTherapeutics), Louise Hecker (PsiloHeal)

More about Longevity Global organization, a non-profit:

RapAdmin

RapClinicalTrial
RapClinicalTrial2752×1536 396 KB

Researchers at the University of Arizona R. Ken Coit College of Pharmacy will begin a double-blind, randomized Phase 3 clinical trial this year to evaluate whether a drug used to prevent organ transplant rejection can also improve older adults’ resilience and immune function.

The clinical trial with the drug, rapamycin, is funded with $12 million in philanthropic support from alumnus R. Ken Coit. Coit graduated from the College of Pharmacy in 1967 and has been a supporter of the college for decades. In 2021, his $50 million naming gift commitment was used to establish endowed faculty positions and student scholarships and to renovate the Coit History of Pharmacy and Health Sciences Museum.

“Ken’s generosity is making possible the first investigator-led clinical trial in the College of Pharmacy,” said Brian Erstad, interim dean of the Coit College of Pharmacy. “His latest gift will enable new opportunities for our researchers to continue to gain further insights into the human lifespan and make new inroads in the development of therapeutics to slow aging.”

“Rapamycin is our best shot on goal for improving resiliency and healthspan as we age,” Coit said. “Several studies have proven that rapamycin can improve vaccine efficacy and improve oral health in older adults. This study will measure the ability for low-dose rapamycin to maintain or improve physical and immunologic functioning in people 65 years and older.”

According to lead investigator Bonnie LaFleur, a professor in the Coit College of Pharmacy, the Phase 3 clinical trial, if it receives final approval from the FDA as expected, is projected to take six years. Participants will be randomized to rapamycin or a placebo that they will take for two years, with an additional year of follow-up. Collaborators will conduct several ancillary studies in parallel with the clinical trial, all with the goal of improving health and well-being in older adults.

Researchers will focus on two main ways to measure the potential effects of rapamycin. The first will gauge the impact of the treatment on physical function, specifically, whether rapamycin changes the transition to frailty, which can significantly impact quality of life. The second will evaluate the levels of an inflammatory marker called IL-6, a measure of inflammation associated with many age-related diseases, including frailty. The researchers want to see if rapamycin can reduce IL-6 levels in the blood.

全文： U of A launches rapamycin clinical trial with philanthropic support of alumnus Ken Coit | University of Arizona News

相关阅读：

RapAdmin

IntensityBest
IntensityBest1710×946 155 KB

For decades, public health guidelines have treated physical activity volume as the primary metric for longevity, often equating long walks with short sprints under the broad umbrella of energy expenditure. A massive new prospective analysis published in 2026 definitively challenges this volume-centric paradigm. By leveraging wearable accelerometer data from nearly 100,000 adults, researchers have established that the intensity of physical activity—specifically the proportion of vigorous physical activity (%VPA)—is a vastly superior predictor of chronic disease prevention than total exercise volume.

The study reveals a non-linear, inverse dose-response relationship between %VPA and the incidence of eight major non-communicable diseases, alongside all-cause mortality. Participants who substituted just over 4% of their total physical activity volume with vigorous exertion saw a 29% to 63% reduction in the hazard ratios for conditions ranging from major adverse cardiovascular events (MACE) and dementia to immune-mediated inflammatory diseases (IMIDs). Notably, these protective effects plateaued at around 4% to 5% VPA for cardiovascular and neurological outcomes, suggesting an easily achievable biological threshold for maximum return on investment.

Crucially, the data disaggregates disease categories by their sensitivity to exercise intensity versus volume. Immune-mediated and inflammatory conditions are almost exclusively intensity-dependent; vigorous activity accounted for a 20.3% population preventable fraction for IMIDs, compared to a mere 1.0% for total activity volume. Conversely, metabolic conditions like type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD) require a combined approach, responding equally well to cumulative energy expenditure (volume) and metabolic stress (intensity). The actionable takeaway is clear: to optimize longevity and healthspan, individuals must cross the vigorous intensity threshold regularly, rather than merely accumulating low-intensity movement.

Context:

相关阅读：

RapAdmin

FerroAging
FerroAging2752×1536 432 KB

For decades, the free radical theory of aging has driven the consumption of generalized antioxidants with mixed, often disappointing, clinical outcomes. A newly published study fundamentally reframes this paradigm by identifying a specific, targetable biological mechanism termed “ferro-aging”. Unlike acute ferroptosis—a rapid, iron-dependent cellular death pathway—ferro-aging is a chronic, low-grade metabolic program that progressively drives cellular senescence and organismal decline. The data demonstrate that iron naturally accumulates across multiple primate organs over time, catalyzing lipid peroxidation. The central executor of this pro-aging shift is acyl-coenzyme A synthetase long-chain family member 4 (ACSL4).

In a high-throughput screen of iron-homeostasis compounds, vitamin C emerged as the most potent suppressor of this aging axis. Crucially, the researchers identified that vitamin C acts not merely as an electron donor, but as a direct structural inhibitor of the ACSL4 enzyme. Target engagement and molecular docking studies confirmed that vitamin C binds directly to the essential catalytic pocket of ACSL4 (residues Thr278, Ser279, and Thr469), mimicking a loss-of-function mutation and halting the thioesterification of polyunsaturated fatty acids.

To validate physiological relevance, the research team conducted a 40-month intervention in aged cynomolgus monkeys. Daily oral supplementation of vitamin C (30 mg/kg, equivalent to approx. 700mg for a human) resulted in a systemic reversal of biological age as measured by multi-omic clocks, encompassing DNA methylation, transcriptomics, and metabolomics. The intervention reversed age-related brain atrophy, restored structural connectivity in the parietal cortex, and improved systemic metabolic markers including triglyceride and insulin levels. This research elevates vitamin C from a generic health supplement to a targeted metabolic modulator of a highly specific lipid-aging mechanism, offering actionable insights for longevity interventions.

In total, the 40-month long oral vitamin C intervention in aged cynomolgus monkeys demonstrated a calculated biological age reversal of three to seven years—representing 10% to 20% of the species’ maximum lifespan—across epigenetic, transcriptomic, and metabolomic clocks, alongside structural brain preservation and metabolic improvements. The most pronounced age-reversal effects were observed in highly metabolic and supportive cell types, such as hippocampal microglia and pancreatic beta cells.

Source:

相关阅读：

RapAdmin

ExerciseEpiClock
ExerciseEpiClock2752×1536 421 KB

While the longevity and biohacking fields are heavily focused on experimental pharmacologics and cellular reprogramming, proving that foundational lifestyle interventions can molecularly reverse biological aging remains a persistent clinical hurdle. Epigenetic clocks—specifically second-generation models like GrimAge, which are trained to predict mortality risk and physiological healthspan rather than mere chronological age—offer a quantifiable metric of biological decay. However, their real-time responsiveness to short-term, non-pharmacological interventions in generally healthy human cohorts has historically lacked clear consensus.

A new clinical pilot study provides compelling evidence that targeted, progressive cardiovascular effort has a rapid and measurable impact on these molecular biomarkers. Researchers implemented a six-month, personalized, cycling-based endurance exercise training (EET) program for 42 physically inactive adults between the ages of 35 and 65. The trial data demonstrated that participants who successfully adhered to the protocol experienced a highly significant 20% increase in cardiorespiratory fitness, measured via maximum oxygen consumption (VO2 max). More importantly, their biological age, as calculated by the GrimAge clock, decreased by an average of 7.44 months relative to their expected chronological aging trajectory.

Crucially, the research team identified that this epigenetic deceleration was tightly correlated with the improvements in VO2 max, rather than mere changes in body weight or fat composition. Furthermore, the study exposed a major confounding biological variable in epigenetic testing: shifts in the immune system. Specifically, fluctuations in the fraction of circulating neutrophils accounted for a massive 74% of the variance in the GrimAge changes. When the statistical models were adjusted to control for these leukocyte shifts, the epigenetic age reduction remained robust and additionally aligned with improved training adherence and body fat reduction.

Interestingly, while the cardiovascular metrics dramatically improved, the participants exhibited a slight decline in bone density and handgrip strength. This clearly signals that cycling alone is an incomplete anti-aging protocol; it requires complementary resistance training to preserve musculoskeletal integrity. Ultimately, this trial underscores that second-generation epigenetic clocks can capture the real-time physiological benefits of endurance exercise, bridging the gap between clinical fitness metrics and molecular longevity.

Source:

RapAdmin

RapamycinMicroGlia
RapamycinMicroGlia2752×1536 471 KB

The utility of rapamycin for extending lifespan is a cornerstone of longevity biotechnology, but its efficacy in neurodegenerative conditions like Alzheimer’s Disease (AD) has yielded conflicting data. This paper clarifies a critical mechanism of action: rapamycin acts primarily by rescuing the metabolic dysfunction of microglia, the brain’s resident immune cells.

During aging and AD progression, microglia accumulate intracellular lipid droplets, transitioning into a dysfunctional, pro-inflammatory state that blunts their ability to clear amyloid-beta (Aβ) plaques. This intervention demonstrates that early, continuous dietary rapamycin suppresses mTOR activity, thereby triggering autophagy (specifically lipophagy) to clear these lipid droplets. By metabolically “unclogging” the microglia, rapamycin restores their lysosomal degradative capacity, allowing them to effectively consume and destroy Aβ fibrils.

Crucially, the study reveals a profound sexual dimorphism in response to mTOR inhibition. While rapamycin successfully reduced Aβ plaque burden and improved spatial working memory and fear memory in female 5xFAD and hAPPNL-G-F mice, male mice exhibited only marginal histological improvements and no significant cognitive rescue. Transcriptomic data aligned with this, showing a much stronger modulation of lipid metabolism and phagocytosis pathways in females. This suggests that the baseline pathology, lipid load, or pharmacokinetic response to rapamycin in AD is heavily sex-dependent, necessitating sex-stratified approaches in human clinical translation.

Source:

相关阅读：

RapAdmin

Rapamycin_Tendon
Rapamycin_Tendon2752×1536 410 KB

Tendon injuries are notoriously difficult to resolve, frequently resulting in disorganized, fibrotic scar tissue that permanently compromises biomechanical function and increases reinjury risk. In longevity and biohacking circles, the mTOR inhibitor rapamycin is frequently lauded for its potent pro-autophagy and anti-fibrotic properties, making it a theoretically attractive candidate to improve connective tissue repair. However, recent data provides a reality check regarding its utility in acute trauma scenarios.

Researchers investigated whether systemic, daily administration of rapamycin could enhance Achilles tendon healing in a rodent needle-puncture injury model. The findings reveal a stark spatial divergence in the drug’s efficacy. Over a three-week observation period, rapamycin successfully attenuated peritendinous fibrosis—the scarring on the outer sheath of the tendon. However, it completely failed to improve the regenerative healing within the intratendinous core.

At the cellular level, immunohistochemistry demonstrated that rapamycin diminished the migration of CD146+ cells to the lesion site during the critical first week of healing. Because CD146+ cells are implicated in the intrinsic reparative and angiogenic processes of the tendon vascular niche, their suppression indicates that acute mTOR inhibition likely stalls the essential proliferative phase of deep tissue regeneration. Furthermore, while the study identified alterations in circulating extracellular vesicle microRNAs (such as the downregulation of miR-128-3p), suggesting a robust systemic response to the drug, this systemic signaling did not translate into localized architectural improvements in the tendon core.

For clinicians and longevity enthusiasts, the takeaway is highly practical: the timing and context of mTOR inhibition are non-negotiable variables. Administering a strong mTOR inhibitor immediately following acute mechanical trauma appears counterproductive for core tissue regeneration. While rapamycin may prevent peripheral adhesions by inhibiting excessive fibroblast activity, it concurrently deprives the damaged tendon core of the anabolic and proliferative signals strictly required to rebuild the extracellular matrix. Ultimately, this study strongly suggests that acute, continuous rapamycin dosing is not a viable therapeutic protocol for early-stage tendon rupture or traumatic injury.

Source: